Metabolic Bariatric Surgery Leads to Similar Benefits for Diabetes Management and Glycaemia in Remitters and Non‐Remitters

Julia S. Kenkre, Sophie Jones, Wann Jia Loh, Iona Davies, Tina Mazaheri, Saleem Ansari, George Lam, Khalefah Malallah, Matthew Waite, Elizaveta Sokol, Veronica Greener, Naim Fakih Gomez, Anna Kamocka, Gianluca Bonanomi, Harvinder Chahal, Chioma Izzi‐Engbeaya, Saira Hameed, Kleopatra Alexiadou, Patricia M. Ortega, Karen O'Donnell, Jonathan Cousins, Christos Tsironis, Sanjay Purkayastha, Toby Prevost, Bernard Khoo, Ahmed R. Ahmed, Tricia Mei‐Mei Tan
Diabetes, Obesity and Metabolism · Wiley · 2026-11-11 · DOI: 10.1111/dom.71522

Аннотация

ABSTRACT Aims Metabolic bariatric surgery (MBS), for example, Roux‐en‐Y gastric bypass (RYGB) can lead to diabetes remission. However, this crude dichotomous outcome fails to fully capture post‐operative improvements in glycaemia and reduced medication burden in people who do not remit. The objectives of this research were to investigate predictors of diabetes remission in a multiethnic cohort and to detail post‐operative improvements in glycaemia and diabetes management. Materials and Methods Prospective observational study of a discovery cohort comprising 67 adults with obesity and Type 2 diabetes, undergoing a standardised RYGB in the United Kingdom or Singapore. Diabetes remission at 12–15 months was the primary outcome. An adjusted HbA1c was calculated using measured HbA1c and the doses/types of diabetes medications to estimate HbA1c without medication. Findings were validated by retrospective clinical audit of a separate UK cohort of 195 individuals undergoing RYGB. Results Diabetes remission was predicted by diabetes duration, measures of treatment intensity and resulting glycaemia (expressed as adjusted HbA1c) and post‐prandial insulin secretion. Both remitters and non‐remitters in the discovery cohort showed similar improvements in adjusted HbA1c (−38.2 ± 17.5 mmol/mol vs. −39.5 ± 15.5 mmol/mol, respectively, p = 0.739), a finding confirmed in the validation cohort. Conclusions While those who do not experience post‐MBS remission have a longer diabetes duration and higher baseline adjusted HbA1c, they benefit similarly from improvements in glycaemia and de‐escalation of treatment as those who remit. We suggest that the likelihood of diabetes remission, as assessed by scoring systems, should not be used as a criterion to recommend MBS to patients.

Читать у издателя →

Похожие статьи